# 🗺️ v2.0 ROADMAP ESTABLISHED
**Date:** January 26, 2026  
**Status:** 🟡 PLANNING COMPLETE  
**Current Version:** v1.6.0-ADVANCED  
**Target Version:** v2.0.0-PARTNER-READY

---

## 🎯 ROADMAP SUMMARY

Successfully established comprehensive **v2.0 Roadmap** with 6 major phases to transform PREDATOR X from proof-of-concept to partner-ready platform.

---

## 📋 THE 6 PHASES

### **Priority Stack:**
```
[1] PK/PD Implementation      → Exposure → Effect (CRITICAL)
    ├─ Extend PK engine output
    ├─ Implement link_pk_to_pd()
    ├─ Wire PK/PD into TrialEngine
    └─ Update Evidence_Package

[2] IIV Full Implementation   → Realistic populations
    ├─ Enhanced population generator
    ├─ Factor-aware PK engine
    └─ Distribution validation

[3] Adaptive Trial Logic      → Modern trial behavior
    ├─ Promote adaptive_rules to behavior
    ├─ Epoch-based adaptation
    └─ Decision logging

[4] Dose Optimization v2      → Regimen selection
    ├─ Target window optimization
    ├─ Coarse-then-refine strategy
    └─ PD target support

[5] Manufacturability         → Feasibility assessment
    ├─ Synthetic accessibility
    ├─ Risk flags
    └─ Formulation hints

[6] Evidence_Package v3       → Partner-ready dossiers
    ├─ v3 schema definition
    ├─ Schema validation
    └─ Migration path (v2→v3)
```

---

## 🎯 WHY THIS MATTERS

### **Current State (v1.6.0-ADVANCED):**
- Exposure-only simulations
- Scaffolds for future features
- Proof-of-concept quality

### **Target State (v2.0.0-PARTNER-READY):**
- Effect-based predictions (PK/PD)
- Production-grade optimization
- CRO-ready dossiers
- Negotiation-grade artifacts

### **The Transformation:**
```
v1.x: "Can we simulate it?"
    ↓
v2.0: "Can we make it, optimize it, and sell it to partners?"
    ↓
Result: Partner conversations shift from "interesting" to "let's sign"
```

---

## ⚡ CRITICAL INSIGHT: PHASE 1 IS EVERYTHING

### **Why PK/PD Implementation Is Priority #1:**

**Current Partner Conversation:**
> "Your platform predicts an AUC of 150 mg·h/L."
> 
> Partner: "That's nice... but what does that mean for efficacy?"

**v2.0 Partner Conversation:**
> "Your drug achieves 75% target inhibition for 12 hours with BID dosing."
> 
> Partner: "Now we're talking. What's the optimal dose?"

### **The Leverage:**
- **Unlocks downstream work:** Adaptive trials, dose optimization need PD
- **Highest partner impact:** Effect > Exposure in all conversations
- **Enables value demonstration:** "We found the optimal dose" vs "We simulated exposure"

---

## 📊 IMPLEMENTATION ORDER (RECOMMENDED)

**Sequential Dependencies:**
```
Phase 1: PK/PD Implementation
    ↓ (Enables effect-based optimization)
Phase 2: IIV Full Implementation
    ↓ (Enables realistic populations)
Phase 3: Adaptive Logic
    ↓ (Requires PD metrics + realistic pops)
Phase 4: Dose Optimization v2
    ↓ (Requires PD targets)
Phase 5: Manufacturability
    ↓ (Independent, can be done anytime)
Phase 6: Evidence_Package v3
    ↓ (Packages everything)
v2.0.0-PARTNER-READY Released
```

**Why This Order:**
1. PK/PD unlocks everything (effect-based decisions)
2. IIV makes simulations credible (realistic variance)
3. Adaptive shows sophistication (modern trials)
4. Dose opt demonstrates value (regimen selection)
5. Manufacturability addresses feasibility (can we make it?)
6. Evidence v3 packages professionally (CRO-ready)

---

## 📄 ROADMAP DOCUMENT

**Location:** `e:\foundation\ROADMAP_v2.0.md`

**Contents:**
- Complete 6-phase breakdown
- Concrete implementation steps for each phase
- Test requirements (unit, integration, system)
- Deliverables checklist
- Success criteria
- Constitutional requirements
- Estimated effort (8-13 sessions)
- Quick start guide

**Status:** ✅ **COMPLETE AND READY**

---

## 🔒 GOVERNANCE

### **Protocol Compliance:**
Every phase must follow the **9-Phase Development Protocol**:
```
1. Implementation      → Isolate component
2. Unit Testing        → Write tests
3. Isolated Test       → Validate alone (100% pass)
4. Integration         → Connect to platform
5. Integration Test    → Test interactions
6. System Test         → Full validation
7. Regression Fix      → Zero tolerance
8. Documentation       → Mandatory
9. Advancement         → Approve next
```

### **Constitutional Requirements:**
Every phase must maintain:
- ✅ L51 (Zero Placeholders)
- ✅ L34 (No Fabrication)
- ✅ ALCOA+ (Evidence Integrity)

---

## 📈 SUCCESS METRICS

### **Technical Metrics:**
```
Phases Complete:         0/6 (0%)
Tests Passing:           TBD (target 100%)
Regressions:             TBD (target 0)
Documentation:           TBD (target complete)
```

### **Capability Metrics:**
```
PK → PD Conversion:      ❌ Not implemented
Realistic Populations:   🟡 Scaffolded
Adaptive Trials:         🟡 Scaffolded
Dose Optimization:       🟡 Basic grid search
Manufacturability:       ❌ Not implemented
Partner-Ready Dossiers:  🟡 v2 schema
```

### **Partner-Readiness:**
```
Effect Predictions:      ❌ Exposure-only
Dose Rationale:          🟡 Basic optimization
Manufacturability:       ❌ Not assessed
Schema Validation:       🟡 v2 only
CRO Handoff Ready:       ❌ Not yet
```

---

## 📊 ESTIMATED EFFORT

| Phase | Complexity | Effort | Status |
|-------|-----------|--------|--------|
| 1. PK/PD | Medium | 2-3 sessions | 🔴 NOT STARTED |
| 2. IIV | Low-Med | 1-2 sessions | 🔴 NOT STARTED |
| 3. Adaptive | Medium | 2 sessions | 🔴 NOT STARTED |
| 4. Dose Opt | Low-Med | 1-2 sessions | 🔴 NOT STARTED |
| 5. Manufact | Medium | 1-2 sessions | 🔴 NOT STARTED |
| 6. Evidence v3 | Low | 1 session | 🔴 NOT STARTED |

**Total:** 8-13 sessions to v2.0

---

## 🚀 NEXT STEPS

### **Immediate Actions:**
1. ✅ Roadmap documented (`ROADMAP_v2.0.md`)
2. ✅ Establishment report created (this document)
3. ⏭️ **BEGIN PHASE 1 (PK/PD Implementation)**

### **Phase 1 Kickoff:**
```bash
# Follow 9-Phase Protocol:

# Phase 1-1: Implementation
# - Modify SimulationEngine.simulate_one_compartment()
# - Implement link_pk_to_pd() in PKPD.py
# - Wire into TrialEngine.run_trial()
# - Update Evidence_Package

# Phase 1-2: Unit Testing
# - Create test_pkpd.py with 8+ tests
# - Test: monotonicity, EC50, AUEC, hill coefficients

# Phase 1-3: Isolated Test
# - Run: python PX_Validation/tests/test_pkpd.py
# - Achieve: 100% pass rate

# Continue through phases 4-9...
```

---

## 🎓 RELATED DOCUMENTS

**Governance:**
- `DEVELOPMENT_PROTOCOL.md` - 9-phase methodology (mandatory)
- `PROTOCOL_VERIFICATION_RECENT_WORK.md` - Protocol proof

**Roadmap:**
- `ROADMAP_v2.0.md` - Complete 6-phase roadmap (this file's source)

**Current State:**
- `README.md` - Current capabilities (v1.6.0-ADVANCED)
- `ADVANCED_FEATURES_IMPLEMENTATION_COMPLETE.md` - Recent work

---

## 📁 FILE STRUCTURE

```
e:\foundation\
├── ROADMAP_v2.0.md                           📋 6-phase roadmap (NEW)
├── DEVELOPMENT_PROTOCOL.md                   🏗️ 9-phase protocol
├── README.md                                 📖 v1.6.0-ADVANCED
└── PX_Audit\reports\
    ├── ROADMAP_v2.0_ESTABLISHED.md           📊 This document (NEW)
    ├── PROTOCOL_ESTABLISHMENT_COMPLETE.md    ✅ Protocol proof
    ├── PROTOCOL_VERIFICATION_RECENT_WORK.md  ✅ Protocol validation
    └── ADVANCED_FEATURES_IMPLEMENTATION_COMPLETE.md  ✅ v1.6 work
```

---

## ✅ ROADMAP ESTABLISHMENT COMPLETE

```
╔══════════════════════════════════════════════════════════════╗
║              v2.0 ROADMAP ESTABLISHED                        ║
╠══════════════════════════════════════════════════════════════╣
║ Status:                 ✅ COMPLETE                         ║
║ Document:               ROADMAP_v2.0.md                     ║
║ Phases Defined:         6/6 ✅                              ║
║ Dependencies Mapped:    ✅                                  ║
║ Protocol Integrated:    ✅                                  ║
║ Success Metrics:        ✅                                  ║
║ Effort Estimated:       ✅ (8-13 sessions)                  ║
║                                                              ║
║ Current Version:        v1.6.0-ADVANCED                     ║
║ Target Version:         v2.0.0-PARTNER-READY                ║
║                                                              ║
║ Next Action:            🚀 BEGIN PHASE 1 (PK/PD)            ║
╚══════════════════════════════════════════════════════════════╝
```

---

## 🎯 THE PATH FORWARD

### **Vision:**
Transform PREDATOR X from:
- **Proof-of-concept** → **Production-grade**
- **Exposure predictions** → **Effect predictions**
- **Interesting demos** → **Partner-ready dossiers**

### **How We'll Get There:**
1. **Follow the roadmap** (6 phases)
2. **Follow the protocol** (9 phases per feature)
3. **Maintain quality** (zero regressions)
4. **Document everything** (partner transparency)

### **When We're Done:**
PREDATOR X will emit **negotiation-grade artifacts** that pharma partners can hand directly to CROs with minimal translation.

---

**Roadmap Established:** January 26, 2026  
**Status:** 🟡 **READY TO BEGIN PHASE 1**  
**Next Milestone:** PK/PD Implementation Complete  

---

**🎉 v2.0 ROADMAP ESTABLISHED - READY FOR PARTNER-GRADE DEVELOPMENT! 🎉**
